XML 95 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202320222021
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$19,423 $37,032 $24,977 
Research services variable consideration1,097 1,560 476 
Total$20,520 $38,592 $25,453 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202320222021
Revenue related to Novartis agreement:
Recognition of upfront license fee$9,568 $31,344 $29,945 
Research services2,611 8,384 7,999 
Total$12,179 $39,728 $37,944 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202320222021
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$132,165 $21,820 $29,224 
Cost-sharing payments for research services, net variable consideration2,684 6,599 13,076 
Total$134,849 $28,419 $42,300 
Revenues recognized under the agreement were as follows (in thousands):
Year Ended December 31,
202320222021
Revenue related to Sanofi agreement:
Recognition of upfront fee$— $677 $34 
Research services— 2,126 3,057 
Milestone achievement— 457 23 
Total$— $3,260 $3,114